Why is Ardelyx stock plunging today?
Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.
How this was made
The 30-second read
Why it matters
The combination of earnings miss plus a narrower, lower 2026 IBSRELA revenue range and removal of XPHOZAH’s long-term target is likely to pressure valuation multiples and near-term expectations for revenue trajectory.
Market read
This is a same-day fundamental reset for ARDX driven by guidance cuts and target withdrawal, not a broad-market move.
What to watch
Investors may be underweighting the cash balance ($281.8M) and the possibility that policy or payer-step-edit dynamics normalize, reducing the duration of the patient-start slowdown.
Background
Ardelyx reported Q2 2026 results and simultaneously revised guidance for IBSRELA and XPHOZAH, citing payer prior authorizations and dialysis payment policy uncertainty.
Ticker impact
Ardelyx shares fell 16% pre-open after Q2 results missed and the company cut 2026 IBSRELA revenue guidance to $350-$370M.
Further downside risk in early sessions unless investors find offsetting evidence on patient starts or XPHOZAH demand.
The article cites multiple same-day fundamental negatives: revenue and EPS miss, lowered IBSRELA guidance, and withdrawal of the XPHOZAH long-term $750M target.
Market effects
Reinforces heightened sensitivity in biopharma to payer authorization friction and guidance credibility.
No direct regional spillover indicated; broader indices were modestly higher.
Limited global relevance beyond US-listed small/mid-cap biopharma sentiment.
Counterpoint
The company still expects profitability in 2027 and reported record demand and prescriptions, suggesting the guidance cut may be more about near-term access mechanics than ultimate demand destruction.
Key entities
- companyArdelyx
Biopharmaceutical company whose Q2 results missed and whose 2026 guidance was cut, driving a sharp pre-open decline.
- productIBSRELA
Ardelyx product facing more stringent payer prior authorizations and step edits, leading to lowered 2026 revenue guidance.
- productXPHOZAH
Ardelyx product with reiterated 2026 revenue guidance but withdrawal of a longer-term $750M revenue target.
- executiveMike Raab
CEO quoted acknowledging headwinds and stating decisive actions were taken.
